A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
Clinical trial NCT07165418 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07165418
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-25
- Primary completion
- 2028-12-30
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.